| Methods |
2‐week washout; 2‐week placebo run‐in; inclusion criteria= mean supine DBP 100‐114 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
Irbesartan 150 mg: n=28(22 males,6 females); mean age=49(5.3) years; baseline supine SBP=170.9(16.1) mm Hg, DBP=106.7(6.4) mm Hg;
Placebo: n=27(18 males,9 females); mean age=54(5.2) years; baseline supine SBP=164.2(14.5) mm Hg, DBP=103.5(3.0) mm Hg |
| Interventions |
Irbesartan 150 mg once daily;
Placebo;
taken at 8 AM |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP using Dinamap 845 oscillometric recorder;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SD not reported, baseline SD reported; calculated SD from N and SE; BP data from Table 1, p. 11; Jadad score=3; funding source= INSERM and Sanofi Research |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
